HOWL Relative Valuation
HOWL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HOWL is overvalued; if below, it's undervalued.
Historical Valuation
Werewolf Therapeutics Inc (HOWL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.01. The fair price of Werewolf Therapeutics Inc (HOWL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.63
Fair
-0.49
PE
1Y
3Y
5Y
-0.04
EV/EBITDA
Werewolf Therapeutics Inc. (HOWL) has a current EV/EBITDA of -0.04. The 5-year average EV/EBITDA is -0.89. The thresholds are as follows: Strongly Undervalued below -5.71, Undervalued between -5.71 and -3.30, Fairly Valued between 1.51 and -3.30, Overvalued between 1.51 and 3.92, and Strongly Overvalued above 3.92. The current Forward EV/EBITDA of -0.04 falls within the Historic Trend Line -Fairly Valued range.
-0.05
EV/EBIT
Werewolf Therapeutics Inc. (HOWL) has a current EV/EBIT of -0.05. The 5-year average EV/EBIT is -1.45. The thresholds are as follows: Strongly Undervalued below -8.64, Undervalued between -8.64 and -5.04, Fairly Valued between 2.14 and -5.04, Overvalued between 2.14 and 5.73, and Strongly Overvalued above 5.73. The current Forward EV/EBIT of -0.05 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Werewolf Therapeutics Inc. (HOWL) has a current PS of 0.00. The 5-year average PS is 21.30. The thresholds are as follows: Strongly Undervalued below -30.37, Undervalued between -30.37 and -4.53, Fairly Valued between 47.14 and -4.53, Overvalued between 47.14 and 72.98, and Strongly Overvalued above 72.98. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.39
P/OCF
Werewolf Therapeutics Inc. (HOWL) has a current P/OCF of -0.39. The 5-year average P/OCF is -2.11. The thresholds are as follows: Strongly Undervalued below -7.75, Undervalued between -7.75 and -4.93, Fairly Valued between 0.72 and -4.93, Overvalued between 0.72 and 3.54, and Strongly Overvalued above 3.54. The current Forward P/OCF of -0.39 falls within the Historic Trend Line -Fairly Valued range.
-0.63
P/FCF
Werewolf Therapeutics Inc. (HOWL) has a current P/FCF of -0.63. The 5-year average P/FCF is -2.86. The thresholds are as follows: Strongly Undervalued below -7.49, Undervalued between -7.49 and -5.17, Fairly Valued between -0.55 and -5.17, Overvalued between -0.55 and 1.77, and Strongly Overvalued above 1.77. The current Forward P/FCF of -0.63 falls within the Historic Trend Line -Fairly Valued range.
Werewolf Therapeutics Inc (HOWL) has a current Price-to-Book (P/B) ratio of 1.03. Compared to its 3-year average P/B ratio of 1.16 , the current P/B ratio is approximately -11.06% higher. Relative to its 5-year average P/B ratio of 1.22, the current P/B ratio is about -15.94% higher. Werewolf Therapeutics Inc (HOWL) has a Forward Free Cash Flow (FCF) yield of approximately -203.34%. Compared to its 3-year average FCF yield of -63.26%, the current FCF yield is approximately 221.46% lower. Relative to its 5-year average FCF yield of -49.84% , the current FCF yield is about 307.98% lower.
1.03
P/B
Median3y
1.16
Median5y
1.22
-203.34
FCF Yield
Median3y
-63.26
Median5y
-49.84
Competitors Valuation Multiple
The average P/S ratio for HOWL's competitors is 38.06, providing a benchmark for relative valuation. Werewolf Therapeutics Inc Corp (HOWL) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HOWL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HOWL in the past 1 year is driven by Unknown.
People Also Watch
UCL
Ucloudlink Group Inc
1.8USD
9.09%
GANX
Gain Therapeutics Inc
2.36USD
-7.45%
CNTB
Connect Biopharma Holdings Ltd
2.21USD
-2.21%
SELX
Semilux International Ltd
0.8215USD
-2.49%
BAYA
Bayview Acquisition Corp
11.75USD
0.00%
PRLD
Prelude Therapeutics Inc
2.77USD
8.20%
VNRX
VolitionRX Ltd
0.2818USD
1.81%
TYGO
Tigo Energy Inc
1.56USD
-2.50%
SELF
Global Self Storage Inc
5.07USD
-0.20%
FKWL
Franklin Wireless Corp
4.1USD
0.00%
Frequently Asked Questions
Is Werewolf Therapeutics Inc (HOWL) currently overvalued or undervalued?
Werewolf Therapeutics Inc (HOWL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.01. The fair price of Werewolf Therapeutics Inc (HOWL) is between to according to relative valuation methord.
What is Werewolf Therapeutics Inc (HOWL) fair value?
HOWL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Werewolf Therapeutics Inc (HOWL) is between to according to relative valuation methord.
How does HOWL's valuation metrics compare to the industry average?
The average P/S ratio for HOWL's competitors is 38.06, providing a benchmark for relative valuation. Werewolf Therapeutics Inc Corp (HOWL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Werewolf Therapeutics Inc (HOWL) as of Jan 07 2026?
As of Jan 07 2026, Werewolf Therapeutics Inc (HOWL) has a P/B ratio of 1.03. This indicates that the market values HOWL at 1.03 times its book value.
What is the current FCF Yield for Werewolf Therapeutics Inc (HOWL) as of Jan 07 2026?
As of Jan 07 2026, Werewolf Therapeutics Inc (HOWL) has a FCF Yield of -203.34%. This means that for every dollar of Werewolf Therapeutics Inc’s market capitalization, the company generates -203.34 cents in free cash flow.
What is the current Forward P/E ratio for Werewolf Therapeutics Inc (HOWL) as of Jan 07 2026?
As of Jan 07 2026, Werewolf Therapeutics Inc (HOWL) has a Forward P/E ratio of -0.49. This means the market is willing to pay $-0.49 for every dollar of Werewolf Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Werewolf Therapeutics Inc (HOWL) as of Jan 07 2026?
As of Jan 07 2026, Werewolf Therapeutics Inc (HOWL) has a Forward P/S ratio of 0.00. This means the market is valuing HOWL at $0.00 for every dollar of expected revenue over the next 12 months.